News

PharmaTimes19h

Upperton Pharma Solutions awarded grant to develop oral vaccine delivery with University of Oxford

Upperton Pharma Solutions has been awarded funding under the first VaxHub Sustainable Platform Funding Call to support the ...
PharmaTimes19h

FDA grants Breakthrough Therapy Designation to lung cancer therapy

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to izalontamab brengitecan ...
PharmaTimes1d

Ogsiveo approved in EU for treatment of desmoid tumors

Merck has announced that the European Commission has granted marketing authorisation for Ogsiveo (nirogacestat) as ...
PharmaTimes1d

Upperton and Oxford join forces to develop oral vaccine formulation

Upperton Pharma Solutions has secured funding from the first VaxHub Sustainable Platform Funding Call to support the ...
PharmaTimes6d

Vedanta’s ulcerative colitis candidate misses phase 2 efficacy target

Despite the outcome, VE202 was well tolerated. Most adverse events were mild or moderate, with no reports of treatment-related serious adverse events. Further analyses on bacterial colonisation and ...
PharmaTimes6d

Mounjaro shows cardiovascular benefit in head-to-head diabetes trial

Kenneth Custer, executive vice president and president, Lilly Cardiometabolic Health, said: “The SURPASS-CVOT results show ...
PharmaTimes6d

Mounjaro shows cardiovascular benefit in head-to-head diabetes trial

Eli Lilly has announced positive topline results from its phase 3 SURPASS-CVOT trial, comparing Mounjaro (tirzepatide) with Trulicity (dulaglutide) in adults with type 2 diabetes and cardiovascular ...